MoonLake Immunotherapeutics
MLTXNASDAQHealthcare● Active
$17.95
+$0.05(+0.28%)
Market Cap$1.3B
P/E Ratio—
52W High$62.75
52W Low$5.95
MoonLake Immunotherapeutics (MLTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MLTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.20B | $0.11B | $0.03B | $0.04B | $0.04B |
| G&A Expenses | $0.04B | $0.03B | $0.02B | $0.02B | $0.00B |
| Total Operating Expenses | $0.24B | $0.14B | $0.05B | $0.07B | $0.05B |
| Operating Income | ($0.24B) | ($0.14B) | ($0.05B) | ($0.07B) | ($0.05B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.23B) | ($0.12B) | ($0.04B) | ($0.06B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.23B) | ($0.12B) | ($0.04B) | ($0.05B) | ($0.05B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.53 | $-1.89 | $-0.73 | $-2.20 | $-1.45 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.05B | 0.03B | 0.04B |
| EBITDA | ($0.22B) | ($0.14B) | ($0.05B) | ($0.06B) | ($0.05B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more MoonLake Immunotherapeutics data
About MoonLake Immunotherapeutics (MLTX) Income Statement
MoonLake Immunotherapeutics (MLTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MLTX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.23B) — a net profit margin of —.
Frequently asked questions
MLTX · 4 questionsMoonLake Immunotherapeutics (MLTX) reported revenue of $0.00B for 2025, down —% year-over-year.
MLTX revenueMLTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08